Laboratory for Cell and Gene Medicine
Our Mission is to bridge the "bench to bedside" gap by creating quality manufacturing processes for cell and gene therapies for treating patients with incurable disease.
Working to Cure the Incurable
At the Stanford Laboratory for Cell and Gene Medicine (LCGM) we're working to cure the incurable alongside world-class researchers. Our state-of-the-art cGMP facility provides support and services to clinical investigators during the entire arc of translational research activities including consulting, technology transfer, process and analytical development, clinical manufacturing and regulatory affairs. Cell and Gene therapy creates opportunities to cure the incurable. Our team of highly skilled professionals work with centers across Stanford Medicine, such as the Center for Definitive and Curative Medicine and the Stanford Cancer Institute, and industry partners to treat patients with incurable disease.
Featured Stories:
Combined stem cell transplant and kidney transplant prove a winning combination against autoimmune FSGS. Full story here.
Earlier this year Dr. Maria Grazia Roncarolo announced her decision to step-down as Director of the Center for Definitive and Curative Medicine and Co-Executive Director of the Laboratory for Cell. In her memorandum Dr. Roncarolo praised the successes brought forth by these centers stating, “The incredible results we have achieved together over the past 8 years are a testament to our collective commitment and determination to curing the incurable. We have built unique infrastructures and incredible teams...together, we have succeeded in closing the gap from the bench to the bedside, proving that translational medicine in stem cell and gene therapy is possible at Stanford Medicine.” In closing Dr. Roncarolo noted that “this is just the beginning”.
Dr. Maria Grazia Roncarolo, MD, is the George D. Smith Professor in Stem Cell and Regenerative Medicine, Professor of Pediatrics and of Medicine, director of the Center for Definitive and Curative Medicine, co-director of the Institute for Stem Cell Biology and Regenerative Medicine, and co-executive director of the Laboratory for Cell and Gene Medicine.
A true champion of cell and gene therapy, Dr. Roncarolo leads efforts to translate scientific discoveries in genetic diseases and regenerative medicine into novel patient therapies, including treatments based on stem cells and gene therapy. She established the Stanford Center for Definitive and Curative Medicine to cure patients with incurable diseases through the development of innovative stem cell-and gene-based therapies.
While studying inherited immune diseases, Dr. Roncarolo discovered a new class of T cells. These cells, called T regulatory type 1 cells, help maintain immune system homeostasis by preventing autoimmune diseases and assisting the immune system in tolerating transplanted cells and organs. Dr. Roncarolo completed the first clinical trial using T regulatory type 1 cells to prevent severe graft-versus-host disease in leukemia patients receiving blood-forming stem-cell transplants from donors who were not genetic matches. Most recently, Dr. Roncarolo received the 2021 Harington Scholar-Innovator Award for her work on New Cell Therapy for Transplantation.
Learn more about Dr. Maria Grazia Roncarolo here.
